Zevra Therapeutics, Inc. ZVRA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $36.22M+6.1% | $34.13M+30.9% | $26.06M+0.7% | $25.88M+26.9% | $20.4M+69.4% | ||
| $1.9M+24.8% | $1.52M+22.8% | $1.24M-90.0% | $12.38M+820% | $1.35M-1.5% | ||
| $34.32M+5.3% | $32.61M+31.3% | $24.83M+83.9% | $13.5M-29.1% | $19.06M+78.5% | ||
| 94.8%-0.8pp | 95.5%+0.3pp | 95.2%+43.1pp | 52.2%-41.2pp | 93.4%+4.7pp | ||
| $4.39M+67.6% | $2.62M-23.7% | $3.43M0.0% | $3.43M+5.4% | $3.26M-61.0% | ||
| $20.78M+2.1% | $20.35M+20.2% | $16.94M-18.5% | $20.78M+6.3% | $19.55M+21.2% | ||
| $25.18M+9.6% | $22.97M+12.8% | $20.37M-15.9% | $24.22M+6.2% | $22.8M-6.8% | ||
| $52.15M— | —— | $4.14M+106% | -$71.04M-1,225% | -$5.36M+65.2% | ||
| 144%— | —— | 15.9%+290pp | -274.5%-248pp | -26.3%+102pp | ||
| $1.71M-12.2% | $1.95M-5.0% | $2.05M+2.1% | $2.01M+2.0% | $1.97M-10.3% | ||
| -$7.34M-319% | $3.35M+165% | -$5.12M-103% | $147.95M+4,194% | $3.45M+170% | ||
| $44.8M+254% | $12.67M+1,396% | -$977K-101% | $76.91M+4,112% | -$1.92M+90.6% | ||
| $6.91M+1,280% | $501K+216% | -$433K-120% | $2.2M+86.0% | $1.18M-92.3% | ||
| $37.89M+211% | $12.17M+2,336% | -$544K-101% | $74.71M+2,511% | -$3.1M+91.3% | ||
| 104.6%+69.0pp | 35.6%+37.7pp | -2.1%-291pp | 288.7%+304pp | -15.2%+282pp | ||
| $0.60+216% | $0.19+2,000% | -$0.01-101% | $1.21+2,117% | -$0.06+91.3% | ||
| $52.51M+251% | $14.98M+230% | $4.54M+107% | -$69.39M-1,769% | -$3.71M+73.0% | ||
| 145%+101pp | 43.9%+26.5pp | 17.4%+286pp | -268.1%-250pp | -18.2%+96.1pp | ||
| $52.15M+257% | $14.61M+253% | $4.14M+106% | -$71.04M-1,225% | -$5.36M+65.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Zevra Therapeutics, Inc.'s revenue?
- Zevra Therapeutics, Inc. (ZVRA) generated $122.3M in revenue over the trailing twelve months, up 201.3% year over year.
- Is Zevra Therapeutics, Inc. profitable?
- Zevra Therapeutics, Inc. reported $124.2M in net income over the trailing twelve months, a 101.6% net margin.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Gross margin is 86.1% and operating margin is -103.9%, with a 101.6% net margin.
- What is Zevra Therapeutics, Inc.'s earnings per share?
- Zevra Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $1.99.
- Where does Zevra Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
